Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

SuppreMol GmbH - Product Pipeline Review - 2013

Published: Oct-2013 | Format: PDF | Global Markets Direct | Number of pages: 25 | Code: MRS - 996

Global Market Directs pharmaceuticals report, SuppreMol GmbH Product Pipeline Review 2013 provides data on the SuppreMol GmbHs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, SuppreMol GmbHs corporate website, SEC filings, investor presentations and featured press releases, both from SuppreMol GmbH and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

SuppreMol GmbH Brief SuppreMol GmbH overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of SuppreMol GmbH human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
Product profiles for late stage and clinical stage products of SuppreMol GmbH with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
Recent updates of the SuppreMol GmbHs pipeline in the last quarter. 
Key discontinued and dormant projects. 
Latest news and deals relating to the products.

Reasons to buy

Evaluate SuppreMol GmbHs strategic position with total access to detailed information on its product pipeline. 
Assess the growth potential of SuppreMol GmbH in its therapy areas of focus. 
Identify new drug targets and therapeutic classes in the SuppreMol GmbHs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
Exploit collaboration and partnership opportunities with SuppreMol GmbH. 
Avoid Intellectual Property Rights related issues. 
Explore the dormant and discontinued projects of SuppreMol GmbH and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 3
SuppreMol GmbH Snapshot 4
SuppreMol GmbH Overview 4
Key Information 4
Key Facts 4
SuppreMol GmbH Research and Development Overview 5
Key Therapeutic Areas 5
SuppreMol GmbH Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products Monotherapy 8
SuppreMol GmbH Pipeline Products Glance 9
SuppreMol GmbH Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
SuppreMol GmbH Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
SuppreMol GmbH Drug Profiles 12
Next Generation Fc gamma Receptor IIB 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
SM-101 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
SM-201 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
SM-301 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SM-401 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SuppreMol GmbH Pipeline Analysis 17
SuppreMol GmbH Pipeline Products by Therapeutic Class 17
SuppreMol GmbH Pipeline Products By Target 18
SuppreMol GmbH Pipeline Products by Route of Administration 19
SuppreMol GmbH Pipeline Products By Mechanism of Action 20
SuppreMol GmbH Recent Pipeline Updates 21
SuppreMol GmbH Locations And Subsidiaries 23
Head Office 23

Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25


List of Tables

SuppreMol GmbH, Key Information 4
SuppreMol GmbH, Key Facts 4
SuppreMol GmbH Pipeline by Indication, 2013 6
SuppreMol GmbH Pipeline by Stage of Development, 2013 7
SuppreMol GmbH Monotherapy Products in Pipeline, 2013 8
SuppreMol GmbH Phase II, 2013 9
SuppreMol GmbH Preclinical, 2013 10
SuppreMol GmbH Discovery, 2013 11
SuppreMol GmbH Pipeline By Therapeutic Class, 2013 17
SuppreMol GmbH - Pipeline By Target, 2013 18
SuppreMol GmbH Pipeline By Route of Administration, 2013 19
SuppreMol GmbH Pipeline Products By Mechanism of Action, 2013 20
SuppreMol GmbH Recent Pipeline Updates, 2013 21 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing